In a research report published Thursday morning. The brokerage assigned a Hold rating to the stock of the biotechnology company.
Recent research reports have been published by other equity research analysts about the company. Jefferies Financial Group downgraded Compugen's rating from hold to underperform in a report published on Wednesday, 8th February. Oppenheimer reiterated an outperform and set an $8.00 price target on shares of Compugen on Tuesday, 28th. SVB Leerink reiterated an outperform ranking on shares of Compugen on Tuesday, 28th February in a report. Five analysts have given the company's shares a buy recommendation, while one analyst gave it a sell. On Thursday, the stock opened at $0.76. Compugen's 52-week low is $0.51, and its 52-week high is $2.36. The stock's 50-day moving average is $0.68, and its 200-day moving average is $0.81.
The last time ) released its quarterly earnings was on Monday, 15th May. The biotechnology company posted ($0.11) earnings per share for the quarter. This beat the consensus estimate ($0.12) of $0.01 by $0.01. In the same quarter last year, Compugen earned ($0.11) in EPS. Research analysts expect Compugen to post an average of -0.4 earnings for the current fiscal.
Compugen: Institutional investors weigh in
Recent changes in hedge fund positions have been made by a number of funds. Seaview Investment Managers LLC increased its position in Compugen from 250.0% to $25,000 during the first quarter. Seaview Investment Managers LLC owns 35,00 shares of biotechnology stock valued at $25,000 after buying an additional 25,000 in the last quarter. Mariner LLC increased its holdings of Compugen shares by 207.3% in the 4th Quarter. Mariner LLC owns 36.831 shares worth $26,000 of the stock of the biotechnology firm after adding 24,844 more shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its holdings of Compugen shares by 216.7% in the 4th Quarter. Vanguard Personalized Indexing Management LLC owns 38.140 shares of stock in the biotechnology company valued at $27,000, after acquiring 26,097 additional shares during the last quarter. Virtu Financial LLC acquired a new position of shares in Compugen valued at $37,000 during the first quarter. Stockman Wealth Management Inc. bought a new share of Compugen in the 4th Quarter valued at $51,000. Stocks of Compugen are owned by 25.34% institutional investors.
Compugen Company Profile
Compugen Ltd. is engaged in the development and commercialization therapeutic and diagnostic biomarker products, including monoclonal antibody and proteins. The company focuses its research and development efforts on immuno-oncology, autoimmune diseases and other related areas. Eli Mintz founded the company with Simchon Faigler and Amir Natan in Holon, Israel, on February 10, 1992.
MarketBeat.com offers a FREE daily email newsletter